Published in Br J Haematol on December 26, 2008
Role for microRNAs in regulating glucocorticoid response and resistance in multiple myeloma. Horm Cancer (2011) 0.90
MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies. ISRN Hematol (2013) 0.80
Epigenetic Pathways in Human Disease: The Impact of DNA Methylation on Stress-Related Pathogenesis and Current Challenges in Biomarker Development. EBioMedicine (2017) 0.75
Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol (2000) 128.08
AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci (1995) 14.81
Transcription termination and the regulation of gene expression. Annu Rev Biochem (1986) 9.97
Histone H3 lysine 4 methylation patterns in higher eukaryotic genes. Nat Cell Biol (2003) 8.82
Profile of histone lysine methylation across transcribed mammalian chromatin. Mol Cell Biol (2006) 5.01
Basic mechanisms of transcript elongation and its regulation. Annu Rev Biochem (1997) 4.63
Steroid receptors: elements for modulation of eukaryotic transcription. Annu Rev Biochem (1976) 4.08
Sequence requirements for premature termination of transcription in the human c-myc gene. Cell (1988) 2.87
RNA polymerase: regulation of transcript elongation and termination. FASEB J (1991) 2.05
DNA methylation models histone acetylation. Nature (1998) 2.04
Identification of intrinsic termination sites in vitro for RNA polymerase II within eukaryotic gene sequences. J Mol Biol (1987) 1.81
Intrinsic sites of transcription termination and pausing in the c-myc gene. Mol Cell Biol (1988) 1.78
Intracellular receptor concentration limits glucocorticoid-dependent enhancer activity. Mol Endocrinol (1987) 1.73
RNA polymerase II transcription termination is mediated specifically by protein binding to a CCAAT box sequence. Mol Cell Biol (1989) 1.67
A human glucocorticoid receptor gene variant that increases the stability of the glucocorticoid receptor beta-isoform mRNA is associated with rheumatoid arthritis. J Rheumatol (2001) 1.51
Leaving a mark: the many footprints of the elongating RNA polymerase II. Curr Opin Genet Dev (2006) 1.46
Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene (2002) 1.45
Variations of the human glucocorticoid receptor gene (NR3C1): pathological and in vitro mutations and polymorphisms. Hum Mutat (2003) 1.37
The glucocorticoid receptor: coding a diversity of proteins and responses through a single gene. Mol Endocrinol (2002) 1.37
Sequence requirements for premature transcription arrest within the first intron of the mouse c-fos gene. Mol Cell Biol (1991) 1.36
Multiple promoters exist in the human GR gene, one of which is activated by glucocorticoids. Mol Endocrinol (2001) 1.35
Purified RNA polymerase II recognizes specific termination sites during transcription in vitro. J Biol Chem (1987) 1.31
SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem (2000) 1.31
Regulation of glucocorticoid receptor expression: evidence for transcriptional and posttranslational mechanisms. Mol Endocrinol (1988) 1.30
Tissue-specific regulation of glucocorticoid receptor mRNA by dexamethasone. J Biol Chem (1987) 1.28
Down-regulation and phosphorylation of glucocorticoid receptors in cultured cells. Investigations with a monospecific antiserum against a bacterially expressed receptor fragment. J Biol Chem (1989) 1.28
Mechanism of glucocorticoid receptor down-regulation by glucocorticoids. J Biol Chem (1988) 1.23
Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-kappaB and lack of I-kappaB involvement. Br J Pharmacol (1999) 1.16
Transcriptional pause, arrest and termination sites for RNA polymerase II in mammalian N- and c-myc genes. Nucleic Acids Res (1999) 1.16
A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA. Blood (1992) 1.14
Quantification and glucocorticoid regulation of glucocorticoid receptor transcripts in two human leukemic cell lines. Biochemistry (2003) 1.12
Characterization of a novel myeloma cell line, MM.1. J Lab Clin Med (1989) 1.11
Identification of transcription stop sites at the 5' and 3' ends of the murine adenosine deaminase gene. J Biol Chem (1990) 1.10
Intragenic sequences of the human glucocorticoid receptor complementary DNA mediate hormone-inducible receptor messenger RNA down-regulation through multiple mechanisms. Mol Endocrinol (1994) 1.03
Autoregulation of glucocorticoid receptor gene expression. Steroids (1991) 1.03
AUUUA motifs in the 3'UTR of human glucocorticoid receptor alpha and beta mRNA destabilize mRNA and decrease receptor protein expression. Steroids (2002) 1.03
The human glucocorticoid receptor promoter upstream sequences contain binding sites for the ubiquitous transcription factor, Yin Yang 1. J Steroid Biochem Mol Biol (1998) 1.02
Sequences in the human c-myc P2 promoter affect the elongation and premature termination of transcripts initiated from the upstream P1 promoter. Mol Cell Biol (1992) 1.02
Regulation of glucocorticoid receptor protein and mRNA levels. Cancer Res (1989) 0.98
Sequence requirements for transcriptional arrest in exon 1 of the human adenosine deaminase gene. Mol Cell Biol (1991) 0.92
Pro-opiomelanocortin gene: a model for negative regulation of transcription by glucocorticoids. J Cell Biochem (1987) 0.91
Inhibition of gene expression by steroid hormone receptors via a negative glucocorticoid response element: evidence for the involvement of DNA-binding and agonistic effects of the antiglucocorticoid/antiprogestin RU486. DNA Cell Biol (1993) 0.89
Glucocorticoid receptor transcriptional isoforms and resistance in multiple myeloma cells. Mol Cancer Ther (2006) 0.88
Triamcinolone acetonide regulates glucocorticoid-receptor levels by decreasing the half-life of the activated nuclear-receptor form. J Biol Chem (1985) 0.88
Glucocorticoid receptors and resistance to glucocorticoids in hematologic malignancies. Leuk Lymphoma (1994) 0.87
Glucocorticoid receptors in immunological subtypes of childhood acute lymphocytic leukemia cells: a Pediatric Oncology Group Study. Cancer Res (1985) 0.82
Glucocorticoid receptors predict response to combination chemotherapy in patients with acute lymphoblastic leukemia. Oncology (1987) 0.82
The relationship of blast cell glucocorticoid receptor levels to response to single-agent steroid trial and remission response in children with acute lymphoblastic leukemia. Leuk Res (1984) 0.82
Transcription elongation of the murine ornithine decarboxylase (ODC) gene is regulated in vitro at two downstream elements by different attenuation mechanisms. Oncogene (1995) 0.79
Glucocorticoid receptors in childhood acute lymphocytic leukemia. Cancer Res (1982) 0.77
Glucocorticoid receptor gene polymorphisms in ACTH-secreting pituitary tumours. Clin Endocrinol (Oxf) (2002) 0.77
Clinical implications of glucocorticoid receptor studies in childhood acute lymphoblastic leukemia. Blood (1980) 0.76
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood (2011) 5.06
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood (2003) 2.06
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood (2005) 2.06
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood (2004) 2.03
Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood (2003) 1.94
AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood (2008) 1.80
hTERT associates with human telomeres and enhances genomic stability and DNA repair. Oncogene (2003) 1.78
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol (2003) 1.67
Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood (2009) 1.62
Intracellular nucleotides act as critical prosurvival factors by binding to cytochrome C and inhibiting apoptosome. Cell (2006) 1.61
Relationship between hip and knee strength and knee valgus during a single leg squat. J Appl Biomech (2006) 1.58
Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cells. Leuk Lymphoma (2012) 1.48
miRNAs and their potential for use against cancer and other diseases. Future Oncol (2007) 1.47
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood (2009) 1.42
Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells. Leuk Lymphoma (2012) 1.40
Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol (2004) 1.40
Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood (2008) 1.36
Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther (2007) 1.34
Clofarabine: past, present, and future. Leuk Lymphoma (2007) 1.31
Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood (2011) 1.27
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood (2005) 1.23
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood (2007) 1.19
A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res (2006) 1.18
Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood (2006) 1.15
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res (2003) 1.13
Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol (2002) 1.12
Hydrogen peroxide inducible DNA cross-linking agents: targeted anticancer prodrugs. J Am Chem Soc (2011) 1.11
Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma. Expert Opin Investig Drugs (2006) 1.09
Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood (2003) 1.09
RNA-directed actions of 8-chloro-adenosine in multiple myeloma cells. Cancer Res (2003) 1.09
MET receptor tyrosine kinase as a therapeutic anticancer target. Cancer Lett (2008) 1.08
Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase. Cancer Res (2007) 1.07
Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP. Blood (2005) 1.06
A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer (2011) 1.06
PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables. Bioinformatics (2009) 1.05
8-Amino-adenosine induces loss of phosphorylation of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2, and Akt kinase: role in induction of apoptosis in multiple myeloma. Mol Cancer Ther (2005) 1.04
Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol (2010) 1.04
Quadriceps femoris electromyogram during concentric, isometric and eccentric phases of fatiguing dynamic knee extensions. J Biomech (2006) 1.04
The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog. Cancer (2005) 1.03
Targeting glucose consumption and autophagy in myeloma with the novel nucleoside analogue 8-aminoadenosine. J Biol Chem (2009) 1.03
RNA-directed agent, cordycepin, induces cell death in multiple myeloma cells. Br J Haematol (2008) 1.02
ROS-activated anticancer prodrugs: a new strategy for tumor-specific damage. Ther Deliv (2012) 1.02
Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood (2010) 1.02
Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J Pharmacol Exp Ther (2011) 1.00
Preclinical activity of 8-chloroadenosine with mantle cell lymphoma: roles of energy depletion and inhibition of DNA and RNA synthesis. Br J Haematol (2009) 0.99
Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood (2010) 0.98
Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma. Blood (2012) 0.96
Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival. Clin Cancer Res (2009) 0.95
8-amino-adenosine is a potential therapeutic agent for multiple myeloma. Mol Cancer Ther (2004) 0.94
A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels. Breast Cancer Res Treat (2009) 0.94
Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics (2011) 0.93
HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma. Br J Haematol (2008) 0.92
Bcl-2 antagonists: a proof of concept for CLL therapy. Invest New Drugs (2013) 0.92
Chain termination and inhibition of mammalian poly(A) polymerase by modified ATP analogues. Biochem Pharmacol (2009) 0.92
8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma. Blood (2010) 0.92
Inhibition of ATP synthase by chlorinated adenosine analogue. Biochem Pharmacol (2009) 0.91
Targeting MET transcription as a therapeutic strategy in multiple myeloma. Cancer Chemother Pharmacol (2008) 0.91
Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line. Cancer Res (2010) 0.91
The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo. Neoplasia (2010) 0.90
Inflammation and survival pathways: chronic lymphocytic leukemia as a model system. Biochem Pharmacol (2010) 0.90
8-Amino-adenosine inhibits multiple mechanisms of transcription. Mol Cancer Ther (2010) 0.90
The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells. Blood (2006) 0.88
Glucocorticoid receptor transcriptional isoforms and resistance in multiple myeloma cells. Mol Cancer Ther (2006) 0.88
Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Pharmacol (2004) 0.88
Mechanisms of cell death of chronic lymphocytic leukemia lymphocytes by RNA-directed agent, 8-NH2-adenosine. Clin Cancer Res (2005) 0.88
Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma. Clin Lymphoma Myeloma Leuk (2013) 0.87
Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res (2002) 0.86
2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer (2005) 0.86
Impact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia. Leuk Lymphoma (2013) 0.85
Targeting the apoptosis pathway in hematologic malignancies. Leuk Lymphoma (2014) 0.85
Transcription inhibition of heat shock proteins: a strategy for combination of 17-allylamino-17-demethoxygeldanamycin and actinomycin d. Cancer Res (2009) 0.85
Caspase activation is required for gemcitabine activity in multiple myeloma cell lines. Mol Cancer Ther (2002) 0.84
Defective molecular timer in the absence of nucleotides leads to inefficient caspase activation. PLoS One (2011) 0.84
Action of (E)-2'-deoxy-2'-(fluoromethylene)cytidine on DNA metabolism: incorporation, excision, and cellular response. Mol Pharmacol (2002) 0.84
The lymphatic tissue microenvironments in chronic lymphocytic leukemia: in vitro models and the significance of CD40-CD154 interactions. Blood (2009) 0.82
Physiotherapy Rehabilitation for Osteoporotic Vertebral Fracture (PROVE): study protocol for a randomised controlled trial. Trials (2014) 0.82
Reactive oxygen species (ROS) inducible DNA cross-linking agents and their effect on cancer cells and normal lymphocytes. J Med Chem (2014) 0.82
Questions about gemcitabine dose rate: answered or unanswered? J Clin Oncol (2007) 0.82
Combination of Pim kinase inhibitor SGI-1776 and bendamustine in B-cell lymphoma. Clin Lymphoma Myeloma Leuk (2013) 0.81
RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics (2013) 0.81
Forodesine: review of preclinical and clinical data. Future Oncol (2010) 0.80
Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues. Leuk Res (2008) 0.80
Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms. PLoS One (2012) 0.80
Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia. Curr Opin Hematol (2008) 0.79
DNA repair initiation induces expression of ribonucleotide reductase in human chronic lymphocytic leukemia cells. Leuk Lymphoma (2013) 0.79
Intracellular succinylation of 8-chloroadenosine and its effect on fumarate levels. J Biol Chem (2010) 0.78
ATP analog enhances the actions of a heat shock protein 90 inhibitor in multiple myeloma cells. J Pharmacol Exp Ther (2011) 0.78
In vitro assessment of nucleoside analogs in multiple myeloma. Cancer Chemother Pharmacol (2004) 0.78
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk (2012) 0.77
Guanosine acts intracellularly to initiate apoptosis in NB4 cells: A role for nucleoside transport. Leuk Lymphoma (2007) 0.77
Nelarabine. Nat Rev Drug Discov (2006) 0.77
Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk (2013) 0.77
Myeloma antioxidant status: the good, the bad and the reactive. Leuk Lymphoma (2009) 0.76
New nucleoside analogues in clinical development. Cancer Chemother Biol Response Modif (2002) 0.76
The novel nucleoside transport system exhibited by NB4 cells, csg, transports deoxyguanosine analogues, including ara-G. Biochem Pharmacol (2003) 0.76
Modifying the immune system to treat chronic lymphocytic leukemia. Leuk Lymphoma (2011) 0.75
Dialing resistance up a Notch. Leuk Lymphoma (2009) 0.75